company background image
4587 logo

PeptiDream TSE:4587 Stock Report

Last Price

JP¥1.41k

Market Cap

JP¥182.2b

7D

2.7%

1Y

-23.3%

Updated

27 Mar, 2024

Data

Company Financials +

4587 Stock Overview

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.

4587 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance2/6
Financial Health5/6
Dividends0/6

PeptiDream Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PeptiDream
Historical stock prices
Current Share PriceJP¥1,406.00
52 Week HighJP¥2,549.00
52 Week LowJP¥1,039.00
Beta0.77
1 Month Change-7.59%
3 Month Change-2.83%
1 Year Change-23.25%
3 Year Change-72.21%
5 Year Change-73.57%
Change since IPO95.62%

Recent News & Updates

PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors

Mar 03
PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors

Recent updates

PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors

Mar 03
PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors

Shareholder Returns

4587JP BiotechsJP Market
7D2.7%-2.0%1.0%
1Y-23.3%-23.2%38.6%

Return vs Industry: 4587 matched the JP Biotechs industry which returned -23.2% over the past year.

Return vs Market: 4587 underperformed the JP Market which returned 38.6% over the past year.

Price Volatility

Is 4587's price volatile compared to industry and market?
4587 volatility
4587 Average Weekly Movement7.6%
Biotechs Industry Average Movement7.8%
Market Average Movement3.9%
10% most volatile stocks in JP Market8.3%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4587 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4587's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.

About the Company

FoundedEmployeesCEOWebsite
2006725Patrick Crawford Reidhttps://www.peptidream.com

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage.

PeptiDream Inc. Fundamentals Summary

How do PeptiDream's earnings and revenue compare to its market cap?
4587 fundamental statistics
Market capJP¥182.23b
Earnings (TTM)JP¥3.04b
Revenue (TTM)JP¥28.71b

60.0x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4587 income statement (TTM)
RevenueJP¥28.71b
Cost of RevenueJP¥11.49b
Gross ProfitJP¥17.22b
Other ExpensesJP¥14.18b
EarningsJP¥3.04b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 14, 2024

Earnings per share (EPS)23.42
Gross Margin59.97%
Net Profit Margin10.57%
Debt/Equity Ratio55.1%

How did 4587 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.